Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
From discovery to clinical development of thymidylate synthase inhibitor ZD9331
March 31st, 2005
The path from discovery to clinical development of thymidylate synthase inhibitor ZD9331 has been studied. According to recent research in the journal Anti-Cancer Drugs, "Thymidylate synthase (TS) has been targeted in cancer therapy for many years. As a result of a prolonged and extensive drug development program specific TS inhibitors have come into clinical practice. Following on from the development of the polyglutamatable TS inhibitor raltitrexed (Tomudex, ZD1694), ZD9331 is a rationally designed third-generation specific inhibitor of TS that does not require polyglutamation for its activity." "Its development was based on the dual...
Source: Women's Health Weekly (2005-03-31)
|
